LP
NRIX icon

Longaeva Partners’s Nurix Therapeutics NRIX Stock Holding History

Longaeva Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,490,202
Closed -$23.1M – 383
2026
Q1 		$23.1M Buy
1,490,202
+562,473
+61% +$9.33M 0.86% 30
2025
Q4 		$17.6M Buy
+927,729
New +$13.3M 1.48% 16

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Longaeva Partners's NRIX Position: Q2 2026 in Review

Longaeva Partners sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 1,490,202 shares — an estimated $23.1M sold.

Longaeva Partners first reported a position in NRIX in Q4 2025 and held it in 2 quarters. The position peaked at $23.1M in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Longaeva Partners reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Longaeva Partners sold 1,490,202 Nurix Therapeutics shares in Q2 2026, an estimated $23.1M.
  • Longaeva Partners first reported a position in Nurix Therapeutics in Q4 2025 and held it in 2 quarters.
  • Longaeva Partners's Nurix Therapeutics position peaked at $23.1M in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.